Search peptides, terms, sources/
Glossary

Phase 1, 2 and 3 Clinical Trials

The staged process by which a new medicine is tested in humans before it can be considered for regulatory approval. Phase 1 trials test safety and dosing in a small number of healthy volunteers. Phase 2 trials test whether a treatment shows a genuine effect in a larger group of people with the relevant condition. Phase 3 trials test it in a much larger, more diverse population to confirm effectiveness and monitor side effects, and usually form the main evidence base for a regulatory decision. Reaching a later phase means a treatment has cleared more evidentiary hurdles, but it does not by itself mean the treatment has been shown to be safe or effective.

Peptides where this matters

  • RetatrutideLY3437943

    Investigational triple GIP, GLP-1 and glucagon receptor agonist studied for weight management. Not licensed in the UK; studied in a Phase 2 trial.

    Metabolic and incretinHuman trialsEvidence reviewed
    ModerateNot licensed in the UK
  • CagrilintideAM833

    Not licensed in the UK. Investigational long-acting amylin analogue studied for weight management, alone and with semaglutide.

    Metabolic and incretinHuman trialsEvidence reviewed
    ModerateNot licensed in the UK
  • Tirzepatide

    Dual GIP and GLP-1 receptor agonist studied in type 2 diabetes and weight management. UK prescription-only medicine; studied in large randomised trials.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongLicensed UK medicine

All glossary terms

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.